Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

iCMLf Conversation: CML Highlights of ASH 2021

Collage Branford Chuah

Panel of experts:

Professor Susan Branford
SA Pathology, Centre for Cancer Biology,
Adelaide (Australia)

Associate Professor
Charles Chuah Thuan Heng
Singapore General Hospital (Singapore) 

Program: (There is no introduction and the video starts right at the first slide)

Resistance overview (Susan Branford)

  • Cancer-related gene mutations in resistant CP/AP CML treated with third generation TKI (Zhang, abstract no. 308)
  • Genomic characterization of ASXL1 G646Wfs* vs other ASXL1 mutations (Johnson, abstract no. 3466)
  • Mutational profiles during the progression of CML (Xue, abstract no. 3596)
  • Prognostic relevance of genetic abnormalities in blast phase CML (Ochi et al. ASH 2020, abstract no. 709/
    Nature Communications 2021;12:2833)

Clinical overview (Charles Chuah Thuan Heng)

  • Post-hoc analysis of responses to ponatinib in pts with CP-CML by baseline BCR-ABL1 level and baseline mutation status in the OPTIC trial (Deininger M et al.)
  • Efficacy and safety results from the ASCEMBL phase 3 study (asciminib vs bosutinib in pts with CP-CML after ≥ 2 prior TKIs: Update after 48 weeks (Mauro MJ et al.)
  • An update of safety and efficacy results from Phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 TKI, in pts with CML and Ph+ ALL failing prior TKI therapies (Cortes JE et al)
  • Updated safety and efficacy of phase 1 study of olverembatinib (HQP1351), a novel 3rd generation TKI in pts with TKI-resistant CML (Jiang Q et al.)
  • Final analysis of a pan European stop tyrosine kinase inhibitor trial in CML: The EURO-SKI study (Mahon FX et al)
  • Treatment-free remissions in newly diagnosed CP-CML pts treated with the combination of nilotinib + pegylated interferon-a 2a versus nilotinib alone in the national phase III PETALs trial (Nicolini FE et al.)
  • The outcome of treatment-free remission after first-line nilotinib or dasatinib in CP-CML patients is different (Nicolini FE et al.)

Q&A Session

If you have any questions or comments to the speaker, please email info@cml-foundation.org.